Inventor · disambiguated record
David Louis Shelton
Also filed as: SHELTON DAVID · SHELTON DAVID L · SHELTON DAVID LOUIS
42 granted patents·43 pending applications·2,205 citations·filing 1994–2021
99Inventor score
Files withGENENTECH INC18RINAT NEUROSCIENCE CORP18TEVA PHARMACEUTICALS INT GMBH9PFIZER6SHELTON DAVID L6
Top patents by PatentIndex Score
85 records- 0198US8871908B2Antibodies specific for Trop-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2012·Granted Oct 28, 2014·86 cites·26 claims
- 0298US7615383B2Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodiesGENENTECH INC·Filed 2006·Granted Nov 10, 2009·99 cites·19 claims
- 0398US5877016AHuman trk receptors and neurotrophic factor inhibitorsGENENTECH INC·Filed 1994·Granted Mar 2, 1999·190 cites·18 claims
- 0497US7425329B2Methods for treating bone cancer pain by administering a nerve growth factor antagonistRINAT NEUROSCIENCE CORP·Filed 2005·Granted Sep 16, 2008·61 cites·17 claims
- 0597US7384632B2Agonist anti-trk-C monoclonal antibodiesGENENTECH INC·Filed 2001·Granted Jun 10, 2008·86 cites·2 claims
- 0697US6027927AHuman trk receptors and neurotrophic factor inhibitorsGENENTECH INC·Filed 1997·Granted Feb 22, 2000·137 cites·17 claims
- 0797US5910574AHuman trk receptors and neurotrophic factor inhibitorsGENENTECH INC·Filed 1995·Granted Jun 8, 1999·140 cites·15 claims
- 0897US5844092AHuman TRK receptors and neurotrophic factor inhibitorsGENENTECH INC·Filed 1994·Granted Dec 1, 1998·219 cites·19 claims
- 0996US9399074B2Antibodies specific for trop-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2014·Granted Jul 26, 2016·19 cites·19 claims
- 1096US7727527B2Anti-NGF antibodies for the therapeutic treatmentsGENENTECH INC·Filed 2002·Granted Jun 1, 2010·74 cites·12 claims
- 1196US7569364B2Anti-NGF antibodies and methods using samePFIZER·Filed 2005·Granted Aug 4, 2009·60 cites·16 claims
- 1296US6153189AHuman TRK receptors and neurotrophic factor inhibitorsGENENTECH INC·Filed 1998·Granted Nov 28, 2000·165 cites·8 claims
- 1395US8007800B2Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibodyPFIZER·Filed 2009·Granted Aug 30, 2011·28 cites·12 claims
- 1494US9676871B2Engineered polypeptide conjugates and methods for making thereof using transglutaminaseSTROP PAVEL·Filed 2011·Granted Jun 13, 2017·40 cites·19 claims
- 1594US8293239B2Methods of treating chronic painPOULSEN KRISTIAN TODD·Filed 2009·Granted Oct 23, 2012·51 cites·14 claims
- 1694US7255860B2Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibodyRINAT NEUROSCIENCE CORP·Filed 2003·Granted Aug 14, 2007·61 cites·11 claims
- 1794US7252822B2Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonistRINAT NEUROSCIENCE CORP·Filed 2003·Granted Aug 7, 2007·83 cites·10 claims
- 1894US6025166AHuman trk receptors and neurotrophic factor inhibitorsGENENTECH INC·Filed 1995·Granted Feb 15, 2000·88 cites·33 claims
- 1994US5766863AKinase receptor activation assayGENENTECH INC·Filed 1995·Granted Jun 16, 1998·109 cites·37 claims
- 2093US9328167B2Methods of treating chronic painLABRYS BIOLOG INC·Filed 2015·Granted May 3, 2016·11 cites·20 claims
- 2193US9029515B2Anti-PCSK9 antibodies with pH dependent antigen bindingPONS JAUME·Filed 2011·Granted May 12, 2015·43 cites·4 claims
- 2293US8623366B2Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptidePIOS ARIEL ATES·Filed 2010·Granted Jan 7, 2014·49 cites·19 claims
- 2393US8298536B2Methods of treating inflammatory painCORRADINI LAURA·Filed 2009·Granted Oct 30, 2012·52 cites·14 claims
- 2491US8540990B2Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the sameROSENTHAL ARNON·Filed 2006·Granted Sep 24, 2013·20 cites·38 claims
- 2591US7655231B2Methods for treating pain by administering a nerve growth factor antagonist and an NSAIDPFIZER·Filed 2004·Granted Feb 2, 2010·61 cites·17 claims
- 2691US5891650AKinase receptor activation assayGENENTECH INC·Filed 1995·Granted Apr 6, 1999·78 cites·29 claims
- 2790US8557245B2Methods for treating bone cancer by administering a nerve growth factor antagonist antibodySHELTON DAVID L·Filed 2012·Granted Oct 15, 2013·14 cites·19 claims
- 2890US8226951B2Methods for treating bone cancer by administering a nerve growth factor antagonist antibodySHELTON DAVID L·Filed 2011·Granted Jul 24, 2012·14 cites·10 claims
- 2989US8034346B2Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the sameRINAT NEUROSCIENCE CORP·Filed 2009·Granted Oct 11, 2011·17 cites·12 claims
- 3088US8481036B2Treatment of chronic prostatitisSHELTON DAVID LOUIS·Filed 2009·Granted Jul 9, 2013·14 cites·17 claims
- 3185US9498530B2Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the sameRINAT NEUROSCIENCE CORP·Filed 2013·Granted Nov 22, 2016·3 cites·11 claims
- 3285US7196165B2PRO363 polypeptidesGENENTECH INC·Filed 2001·Granted Mar 27, 2007·6 cites·9 claims
- 3383US8715673B2Staphylococcus aureus specific antibodies and uses thereofRINAT NEUROSCIENCE CORP·Filed 2012·Granted May 6, 2014·4 cites·15 claims
- 3483US8591898B2Treatment of interstitial cystitisMILLS IAN WILLIAM·Filed 2008·Granted Nov 26, 2013·16 cites·7 claims
- 3581US11602525B2Antibody-drug conjugates with high drug loadingRINAT NEUROSCIENCE CORP·Filed 2015·Granted Mar 14, 2023·2 cites·17 claims
- 3679US10323085B2Methods of treating fibromyalgiaTEVA PHARMACEUTICALS INT GMBH·Filed 2018·Granted Jun 18, 2019·1 cites·18 claims
- 3778US10323086B2Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the sameRINAT NEUROSCIENCE CORP·Filed 2016·Granted Jun 18, 2019·1 cites·16 claims
- 3877US10597448B2Methods for treating visceral pain associated with interstitial cystitis by administering antagonist antibodies directed against calcitonin gene-related peptideTEVA PHARMACEUTICALS INT GMBH·Filed 2018·Granted Mar 24, 2020·1 cites·6 claims
- 3976US10100114B2Antibodies specific for TROP-2 and their usesRINAT NEUROSCIENCE CORP·Filed 2016·Granted Oct 16, 2018·1 cites·9 claims
- 4074US2021317196A1Methods of Treating Chronic PainTEVA PHARMACEUTICALS INT GMBH·Filed 2020·Application pending·0 cites
- 4174US2022017608A1Methods of Treating Inflammatory PainTEVA PHARMACEUTICALS INT GMBH·Filed 2021·Application pending·0 cites
- 4273US2020399357A1Anti-NGF Antibodies for Treatment of Various DisordersGENENTECH INC·Filed 2020·Application pending·0 cites
- 4372US9340610B2Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the sameRINAT NEUROSCIENCE CORP·Filed 2013·Granted May 17, 2016·1 cites·13 claims
- 4472US2022169713A1Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the sameRINAT NEUROSCIENCE CORP·Filed 2021·Application pending·0 cites
- 4570US2020148752A1Methods of Treating Inflammatory PainTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Application pending·0 cites
- 4670US2021047397A1Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptideTEVA PHARMACEUTICALS INT GMBH·Filed 2020·Application pending·0 cites
- 4768US2020087384A1Methods of treating chronic painTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Application pending·0 cites
- 4867US2021115159A1Engineered polypeptide conjugates and methods for making thereof using transglutaminasePFIZER·Filed 2020·Application pending·0 cites
- 4967US2020157201A1Methods for treating osteoarthristis pain by administering a nerve growth factor antagonist and compositions containing the sameRINAT NEUROSCIENCE CORP·Filed 2019·Application pending·0 cites
- 5067US2010003261A1agonist anti-trk-c monoclonal antibodiesDEVAUX BRIGITTE·Filed 2009·Application pending·0 cites
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David Louis Shelton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →